Solid Biosciences Inc. (SLDB) Stock Forecast
SLDB analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.64 / 5 from 14 analysts
- Price target
- $18.71 average of analyst targets
- Upside to target
- +238.4% from the latest close
- Next earnings
- November 2, 2026 EPS estimate $-0.37
- 52-week range
- $3.93 – $11.15
SLDB analyst ratings
14 analystsNumber of analysts at each rating.
SLDB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SLDB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.41 | −$0.53 | −$0.34 | −$0.48 | +14.0% | 14 |
| Current fiscal year (2026) | −$1.76 | −$2.39 | −$1.55 | −$1.99 | +11.8% | 14 |
| Next fiscal year (2027) | −$1.71 | −$2.40 | −$1.30 | −$1.76 | +2.6% | 14 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SLDB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 12 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 12 |
| Next fiscal year (2027) | $8.6M | $0 | $82.2M | 0.0% | 12 |
SLDB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SLDB revenue: reported and forecast
SLDB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.47 | −$0.42 | −$0.41 | −$0.41 | −$0.41 | −13.1% | 8 up · 1 down |
| Current fiscal year (2026) | −$1.96 | −$1.77 | −$1.76 | −$1.76 | −$1.76 | −10.3% | 0 up · 1 down |
| Next fiscal year (2027) | −$1.96 | −$1.75 | −$1.75 | −$1.70 | −$1.71 | −12.6% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SLDB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SLDB beat in 4 of 12.
What analysts expect from SLDB
14 analysts cover Solid Biosciences; their consensus rating is strong buy (4.64 on a 1–5 scale, where 5 is a strong buy). The average price target is $18.71, 238.4% above the latest close of $5.53. Analysts expect earnings of −$1.76 per share for 2026, +11.8% from a year earlier. For 2027 the average estimate is −$1.71 per share on revenue of $8.6 million. Solid Biosciences beat the EPS estimate in 4 of the last 12 quarters.
Related: SLDB income statement, SLDB key metrics, SLDB chart. See the SLDB stock overview for the latest quote and news.
SLDB forecast FAQ
What is Solid Biosciences's price target?
The average analyst price target for Solid Biosciences is $18.71, 238.4% above the latest close of $5.53.
Is Solid Biosciences a buy, hold or sell?
Of 14 analysts covering Solid Biosciences, 9 rate it a strong buy, 5 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Solid Biosciences's EPS forecast?
Analysts forecast −$1.76 per share for 2026 (range −$2.39 to −$1.55); for 2027 the estimate is −$1.71.
When does Solid Biosciences report earnings?
Solid Biosciences is expected to report results for the quarter ending September 30, 2026 on November 2, 2026 after the market closes; the EPS estimate is $-0.37.
Does Solid Biosciences usually beat earnings estimates?
Solid Biosciences reported EPS at or above the analyst estimate in 4 of the last 12 quarters.